There was a time when there was no way of managing allergic diseases except by avoidance of allergens. Avoidance could not be effectively managed against some aeroallergens such as pollens, mold spores, and house dust. Allergists, particularly in the United States, began to use injection therapy and the treatment evolved to modern methodology for allergen immunotherapy (IT). As new treatments for allergy appeared, including H1 blockers and topical corticosteroids, many allergists thought there was no future for IT. However, IT has persisted and efficacy has been proven. Allergen IT remains a valuable therapy for allergic rhinitis and prevention of asthma. The true allergic asthmatic will often have chest symptoms improve with IT. Allergen IT can prevent the development of asthma in children with allergic rhinitis. Multiseasonal allergic rhinitis in a young person can require years of symptomatic therapy that is costly, tedious, and results in control but no alteration of the course of the allergic disease. Our approach should be proper education of the appropriate use of IT.
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.